Natalizumab-PML survivors with subsequent MS treatment
نویسندگان
چکیده
منابع مشابه
Natalizumab-PML survivors with subsequent MS treatment
Objective: To describe the clinico-radiologic outcome of MS patients with natalizumab-related progressive multifocal leukoencephalopathy (Nz-PML) surviving and receiving diseasemodifying therapy (DMT). Methods: We describe clinical and radiologic evolution of Nz-PML survivors in an observational retrospective multicenter cohort to clarify the effect of different subsequent MS DMT strategies. Tw...
متن کاملSevere early natalizumab-associated PML in MS: Effective control of PML-IRIS with maraviroc
Case report. A 55-year-old Caucasian HIV-negative man diagnosed with relapsing-remitting MS in 2013 and an Expanded Disability Status Scale (EDSS) score of 2.0 had received 20 infusions of natalizumab over 21 months without a history of prior immunotherapy. John Cunningham–virus (JCV) antibodies were positive at the initiation of treatment (index: 0.4). Natalizumab was then discontinued because...
متن کاملMaraviroc as possible treatment for PML-IRIS in natalizumab-treated patients with MS
Progressive multifocal leukoencephalopathy (PML) is a serious complication of natalizumab treatment in patients with relapsing-remittingMS (RRMS) with 638 confirmed cases as of March 2016. Therapeutic reestablishment of cerebral immune surveillance in PML management is complicated by immune reconstitution inflammatory syndrome (IRIS), an exuberant inflammatory response that aggravates damage ca...
متن کاملPathologic Findings of Chronic PML-IRIS in a Patient with Prolonged PML Survival Following Natalizumab Treatment
Immune reconstitution inflammatory syndrome (IRIS) is a common complication during treatment for natalizumab-associated progressive multifocal leukoencephalopathy (PML). Although severe IRIS can result in acute worsening of disability and is associated with poor prognosis, effective immune reconstitution may account for the high survival rate of this cohort of PML patients. We present pathologi...
متن کاملBrainstem PML lesion mimicking MS plaque in a natalizumab-treated MS patient.
A 47-year-old woman with relapsing-remitting multiple sclerosis (MS), treated with natalizumab for 14 months, reported dysphagia. Brain MRI demonstrated small fluid-attenuated inversion recovery–hyperintense T1-hypointense unenhancing lesions of the right pons and left medulla initially interpreted as new MS plaques (figure 1), but increased and became confluent over 3 months (figure 2). CSF de...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Neurology - Neuroimmunology Neuroinflammation
سال: 2017
ISSN: 2332-7812
DOI: 10.1212/nxi.0000000000000346